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Abstract
Background: Pitavastatin is the newest statin available in Brazil and likely the one with fewer side effects. Thus, pitavastatin 
was evaluated in hypercholesterolemic rabbits in relation to its action on vascular reactivity.
Objective: To assess the lowest dose of pitavastatin necessary to reduce plasma lipids, cholesterol and tissue lipid 
peroxidation, as well as endothelial function in hypercholesterolemic rabbits.
Methods: Thirty rabbits divided into six groups (n = 5): G1 - standard chow diet; G2 - hypercholesterolemic diet for 30 days; 
G3 - hypercholesterolemic diet and after the 16th day, diet supplemented with pitavastatin (0.1 mg); G4 - hypercholesterolemic 
diet supplemented with pitavastatin (0.25 mg); G5 - hypercholesterolemic diet supplemented with pitavastatin (0.5 mg); 
G6 - hypercholesterolemic diet supplemented with pitavastatin (1.0 mg). After 30 days, total cholesterol, HDL, triglycerides, 
glucose, creatine kinase (CK), aspartate aminotransferase (AST), alanine aminotransferase (ALT) were measured and LDL 
was calculated. In-depth anesthesia was performed with sodium thiopental and aortic segments were removed to study 
endothelial function, cholesterol and tissue lipid peroxidation. The significance level for statistical tests was 5%. 
Results: Total cholesterol and LDL were significantly elevated in relation to G1. HDL was significantly reduced in G4, G5 
and G6 when compared to G2. Triglycerides, CK, AST, ALT, cholesterol and tissue lipid peroxidation showed no statistical 
difference between G2 and G3-G6. Significantly endothelial dysfunction reversion was observed in G5 and G6 when 
compared to G2.
Conclusion: Pitavastatin starting at a 0.5 mg dose was effective in reverting endothelial dysfunction in hypercholesterolemic 
rabbits. (Arq Bras Cardiol. 2014; 103(1):4-12)
Keywords: Hydroxymethylglutaryl - CoA Reductase Inhibitors; Endothelial Dysfunction; Rabbits; Hypercholesterolemia.
Introduction 
Inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme 
A reductase (HMG-CoA), the statins, are potent inhibitors of 
cholesterol biosynthesis in the liver by blocking the conversion to 
mevalonate1. Clinical studies with simvastatin (4S) and pravastatin 
(WOSCOPS) demonstrated that statins act by decreasing 
the concentration of cholesterol in the blood, decreasing the 
incidence of myocardial infarction and its mortality2,3. 
Aiming at correlating decreases in mortality with the 
atherosclerotic plaque size, studies were carried out with 
different commercial products of statins. Aware of changes 
in lipid profile, the studies MARS4 and REGRESS5 showed 
that there were stabilization and regression of atherosclerosis 
as assessed by coronary angiography. 
Ribeiro Jorge et al6 in 1994 suggested that statins might 
have an antioxidant action when they observed that 
hypercholesterolemic rabbits showed improvement of 
endothelial dysfunction that was disproportionate to lipid 
reduction, when treated with pravastatin. This observation 
was once again seen in 19977, when the rapid reversal of 
hypercholesterolemia with statins was studied in the same 
animal model. These actions, in addition to lowering cholesterol 
known as pleiotropic effects, refer to endothelial function 
protection, anti-inflammatory and anti-thrombotic action and 
stabilization of atherosclerotic plaque, among others8-14. 
Pitavastatin is the latest available statin in the market, also 
known as nisvastatin and itavastatin. It was developed in 
2003 in Japan, and approved in 2009 by the U.S. Food and 
Drug Administration of the United States of America, being 
the seventh statin to be developed and commercialized15,16.
It is a synthetic and lipophilic statin, of which 
pharmacokinetics and pharmacodynamics have distinct 
properties compared with other statins and can offer greater 
pleiotropic effects in relation to endothelial function, 
inflammation, oxidative stress and antithrombosis. It is 
minimally metabolized in the liver and primarily metabolized 
by enzymes CYP2C9 and CYP2C8, showing bioavailability 
of 80% of the administered dose17,18. The low affinity of 
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pitavastatin to CYP3A4 reduces interactions with other 
drugs metabolized by this enzyme and can decrease toxic 
manifestations19 -21. 
To date, no clinical or experimental study on the 
pitavastatin was found in the Brazilian literature and 
thus, the aim of this study was to verify the action of this 
statin, particularly in decreasing endothelial dysfunction in 
experimental hypercholesterolemia, as well as defining its 
lowest effective dose for this purpose.
Methods
The experimental protocol was approved by the Ethics 
Committee for Animal Experimentation (EAEC)-IB-UNICAMP, 
under n. 2528-1. 
The animals were fed 100g a day of standard chow 
with the following composition (g/100): Proteins, 16.00; 
Carbohydrates, 45.00; Fibers, 20.00; Fat, 5.00 and 
Ash, 14.00. We studied 30 New Zealand male rabbits 
initially weighing from 2.0 to 2.5 kg, which were divided 
into six groups. In the group considered as control in 
relation to hypercholesterolemic ones (G1), the rabbits 
were sacrificed after one month of standard diet and 
adaptation to the biothery. The other 25 rabbits received 
a hypercholesterolemic diet, containing standard chow 
supplemented with 0.5% cholesterol and 10% coconut oil. 
With the exception of the hypercholesterolemic control 
group (G2), the other groups were treated with pitavastatin 
(Kowa Company,  Nagoya,  Japan) dur ing the las t 
15 days, by gavage, at doses of 0.1 mg/animal/day (G3), 
0 25 mg/animal/day (G4), 0.5 mg/animal/day (G5) and 
1 mg/animal/day (G6). 
Biochemical analysis
Total plasma cholesterol, HDL-cholesterol (high-density 
lipoproteins), triglycerides, glucose, AST (aspartate 
aminotransferase), ALT (alanine aminotransferase) and 
creatine kinase were measured using enzymatic kits (Laborclin, 
Bioliquid, Pinhais, PR, Brazil), and the reading was performed 
by spectrophotometry (Thermo Spectronic, Genesys 10 uv, 
Rochester, NY, USA) with a wavelength of 500 nm. LDL was 
calculated using Friedewald formula.
Tissue Cholesterol 
At the end of the experiment, the animals were sacrificed 
and the thoracic aorta was removed. Tissue cholesterol was 
measured in segments according to the method of Naito and 
David22. In brief, the specimens were dried and homogenized 
at 4° C in 5 mL of Tris HCl buffer, pH 7.4, plus 0.01 NaNO3. 
Total lipids were extracted and homogenized in 10 vol of 
chloroform-methanol. The extracted total cholesterol was 
measured by enzymatic kits. 
Tissue lipid peroxidation
One segment of the thoracic aorta was homogenized 
with trichloroacetic acid (1 g tissue + 10 vol 20% TCA). After 
centrifugation, 0.67% thiobarbituric acid volume was added 
and the mixture was heated at 100 ° C for 20 minutes. 
The concentration of malondialdehyde was calculated from 
the absorbance of 532 nm using extinction coefficient of 
1.49 x 10-5 expressed as nmoL/mg tissue x 10-7 23. 
Endothelial function
 Endothelial function was measured in the thoracic aorta 
segments of approximately 5 mm, with intact endothelium, 
suspended in a recipient with a capacity of 10 mL in Krebs-
Henseleit solution at 37° and pH 7.4 and heated to 37º C. The 
solution was continuously aerated with a carbogen mixture 
containing 95% oxygen and 5% carbonic gas. The segments 
were mounted on two metal hooks attached to a support in 
the container and the force transducer (Narco, 40 Narcotrace, 
Texas, USA). Then they were left to equilibrate for 60 minutes 
with replacement of the Krebs Henseleit solution every 
20 minutes. The segments were stretched to a basal tension 
of 1 g. All segments of the aorta were contracted with 
NE (10-7M) and, after stabilization, ACh was added 
cumulatively (10-8 to 10-5 M)6,24 and relaxation was verified. 
Statistical Analysis 
The SAS for Windows (Statistical Analysis System) software, 
version 9.2 (SAS Institute Inc., 2002-2008, Cary, NC, USA) 
was used in the statistical analysis.
ANOVA with rank transformation was used to compare 
treatment groups through the collected variables, 
followed by Tukey test, to locate the differences. When 
comparing endothelial function to locate the differences in 
concentrations between the groups, the contrast profile test 
was used. The significance level for statistical tests was 5%. 
Results
The results of means and standard deviations of the 
different parameters studied are shown in Table 1. 
Figure 1, depicting total cholesterol in the end of the 
experiment, showed that there was a decrease in total 
cholesterol in groups G5 (25.8% reduction) and G6 (25.7%), 
where the rabbits were treated with 0.5 and 1.0 mg of 
pitavastatin, when compared to the hypercholesterolemic 
group G2, with statistically significant difference. 
Figure 2, depicting LDL, showed that there was a decrease 
in G5 (20.07%) and G6 (26.62%), with no statistically 
significant difference when compared to G2.
Figure 3, depicting HDL, showed that a decrease occurred 
in G3 (40.88%), G5 (56.68%) and G6 (56.53%) when 
compared to G2, with a statistically significant difference. 
Figure 4, depicting triglycerides, showed that a decrease 
occurred in G3 (44.62%), G4 (33.53%), G5 (52.05%) and 
G6 (45.56%), but with no statistically significant difference 
when compared to G2.
Figure 5, depicting tissue cholesterol, showed a decrease in 
groups G5 (28.2%) and G6 (20.09%), but with no statistically 
significant difference when compared to G2. 
Figure 6, depicting lipid peroxidation, showed a decrease 
in G5 (26.25%) and G6 (31.25%), with no statistically 
significant difference compared to G2. 
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Figure 1 – Total cholesterol in all groups expressed as mean and standard deviation. 
* p < 0.05 in relation to G2.
Table 1 – Results of groups G1 to G6 with means and standard deviations 
G1 G2 G3 G4 G5 G6
Col (mg/dL) 63.6 ± 4.3 753.9 ± 32.0 650.5 ± 212.5 705.3 ± 164.0 559.6 ± 203.6 527.6 ± 100.9
HDL (mg/dL) 16.5 ± 3.7 61.4 ± 8.8 *36.3 ± 15.0 *25.2 ± 10.9 *26.6 ± 12.5 *26.7 ± 5.7
LDL (mg/dL) 26.6 ± 3.9 650.0 ± 33.3 599.7 ± 196.3 663.0 ± 161.1 519.6 ± 202.3 477.7 ± 103.4
Trig (mg/dL) 104.2 ± 16.2 212.5 ± 99.9 117.7 ± 32.9 141.2 ± 36.5 101.9 ± 22.5 115.7 ± 15.0
Gli (mg/dL) 115.8 ± 19.2 127.3 ± 28.9 114.6 ± 25.5 123.5 ± 21.6 119.8 ± 23.7 94.7 ± 26.2
Col tec (mg/g) 21.6 ± 4.9 28.7 ± 4.8 22.8 ± 2.0 29.1 ± 7.8 20.4 ± 5.6 22.7 ± 4.5
Perox (ng/mg de prot) 5.1 ± 0.6 8.0 ± 1.9 5.7 ± 1.6 5.3 ± 1.4 5.9 ± 1.2 5.5 ± 1.4
Rel Máx (%) 93.2 ± 6.7 60.2 ± 12.64 62.3 ± 12.1 61.3 ± 11.7 *80.40 ± 5.1 *79.8 ± 12.0
Cknac (U/l) 236.1 ± 79.9 354.0 ± 62.3 243.8 ± 89.0 200.5 ± 88.7 336.1 ± 135.2 298.3 ± 118.6
AST (U/l) 35.7 ± 15.4 25.9 ± 8.3 50.0 ± 24.5 22.7 ± 8.3 30.0 ± 9.1 34.7 ± 10.8
ALT (U/l) 20.3 ± 11.2 25.1 ± 6.7 37.2 ± 18.6 36.1 ± 13.8 *18.3 ± 6.1 30.1 ± 6.8
Col: total cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TG: triglycerides; Glu: glucose; Tissue Col: tissue cholesterol; Perox: peroxidation 
tissue (ng / mg protein); Rel Max (%): endothelial function; Cknac: creatine phosphokinase; AST: aspartate aminotransferase; ALT: alanine aminotransferase.  
* p < 0.05 in relation to G2.
Figure 7 shows an improvement in endothelial function in G5 
and G6 in relation to group G2, which was statistically significant.
Regarding glucose, creatine kinase, AST and ALT, there 
were no statistically significant alterations between the 
groups (Table 1).
Discussion
Severa l  d i f ferent  s ta t ins  are  ava i lab le  in  the 
pharmaceutical market, acting through the inhibition of 
3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) 
reductase, which makes them members of a group of a 
specific class of drugs, all with the precise indication of 
hypercholesterolemia reduction. Molecular pharmacokinetic 
and pharmacodynamic modifications have been performed 
to differentiate the statins, almost always seeking the more 
effective blocking of HMGCoA reductase and thus, better 
control of plasma lipids, but also for the purpose of drug 
individualization, in addition its generic quality.
Pitavastatin is the newest statin in the market, starting in 2003 
in Japan and currently available in Brazil25. To the best of our 
knowledge, this constitutes the first experimental study available 
in the Brazilian literature, to date, which evaluated pitavastatin 
action on plasma and tissue lipids, lipid peroxidation and 
vascular reactivity, seeking to identify the lowest dose at which 
it can be effective in controlling these parameters. Moreover, 
clinical studies have not been published in the national literature 
addressing the different aspects involving pitavastatin. 
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Figure 2 – LDL-col in all groups expressed as mean and standard deviation.
* p < 0.05 in relation to G2.
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The addition of fat to the standard chow fed to the 
rabbits has been the most widely used model for induction 
of experimental hypercholesterolemia and it was effective 
in this study. The results shown in Table 1 showed that 
group G2 showed significantly higher elevations in serum 
lipids than those in G1, fed the standard chow. The same 
occurred with the tissue parameters, with elevations in total 
cholesterol, lipid peroxidation and reduced endothelial 
function in aortic segments. 
The pitavastatin dose proposed for human use ranges from 
1 to 2 mg/day, with a maximum dose of 4 mg/day, whereas in 
experimental studies, a dose < 1 mg/kg/day has been used, with 
no reports of groups of animals receiving increasingly higher 
doses, as in the present study19,26,27. The pitavastatin doses used 
in this study, although lower than the lowest used in humans, 
are high for rabbits, considering the differences between the 
species, especially weight. However, they are necessary to achieve 
the effect of cholesterol reduction in these animals, which was 
observed only with a minimum dose 0.5 mg/animal. Differences 
in metabolism between species may probably explain why high 
doses are not toxic or lethal to some of them. Not only were 
the doses different regarding their action on lipids, but also their 
time of use. In the present study, only 15 days of drug use were 
sufficient for the lipid-lowering action of pitavastatin to occur, 
while other studies used at least 12 weeks19.
These data are similar to those observed in studies using other 
statins, when doses are optimized for a same total cholesterol 
percentage reduction28. A clinical study has demonstrated that 
pitavastatin improves peripheral microvasculature function verified 
through reactive hyperemia measured by arterial tonometry 
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Figure 3 – HDL-col in all groups expressed as mean and standard deviation. 
* p < 0.05 in relation to G2.
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Figure 4 – Triglycerides in all groups expressed as mean and standard deviation.
in hypercholesterolemic individuals with coronary artery disease, 
only two hours after oral administration of the drug, demonstrating 
the promptness of drug action in improving endothelial function, 
regardless of its action on plasma cholesterol29. 
The results shown in Table 1 and Figure 7 demonstrated 
that pitavastatin was effective in improving vascular reactivity, 
as there was a significant improvement in endothelial 
dysfunction in the treated groups when compared to the 
hypercholesterolemic group. However, this effect occurred 
only with doses ≥ 0.5 mg, meaning that lower doses are 
unable to exercise the same effect during the time period of the 
experiment. Similar results in endothelial dysfunction reversal 
by pitavastatin have been reported in other experimental 
studies19 and in humans29 without great differences from those 
observed when other statins were assessed28,30-32. 
The improvement in endothelial dysfunction cannot be 
determined only by LDL reduction, although this reduction 
has occurred, as shown in Table 1 and Figure 2, because 
the absolute values  still remained much higher than in 
the G1 group, not hypercholesterolemic. However, the 
percentage of relaxation was very close to that of G1. 
Oxidative stress involving LDL in hypercholesterolemia 
has been held responsible for the endothelial dysfunction 
observed in these situations and was one of the goals of this 
study. Even without full control of hypercholesterolemia, 
one can achieve reversal of endothelial dysfunction by 
reducing oxidative stress. This effect has been produced 
by statins and occurs with pitavastatin, as observed in the 
results, as there was a decrease in tissue lipid peroxidation 
in relation to G2, in the treated groups.
Figure 5 – Tissue cholesterol in all groups expressed as mean and standard deviation.
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Figure 6 – Tissue peroxidation in all groups expressed as mean and standard deviation.
Figure 7 – Endothelial function in all groups expressed as mean and standard deviation.
*p < 0.05 in relation to G2.
Closely related to both situations, an improvement in 
endothelial dysfunction and decreased lipid oxidation is the 
reduction in tissue cholesterol, as reported in Table 1 and 
Figure 5, as well as in previous studies28,30-32. However the 
reduction in tissue cholesterol and lipid peroxidation occur 
similarly in all treated groups, unlike endothelial dysfunction 
reversal, which was observed only in the groups where animals 
received higher doses of pitavastatin (G5 and G6). 
A literature study that used the same experimental 
model26 aimed to evaluate the effect of pitavastatin and 
probucol on atherosclerosis progression by studying oxidative 
stress. For that purpose, superoxide dismutase and the 
expression of peroxisome proliferator-activated receptors 
(PPARs) were used as parameters. The authors observed that, 
at a dose of 0.05 mg / kg / day, pitavastatin was effective 
in reducing oxidative stress without any action on serum 
9
Original Article
Almeida & Ozaki
Pitavastatin and rabbits
Arq Bras Cardiol. 2014; 103(1):4-12
cholesterol levels. Thus, it appears that pitavastatin acts on 
other mechanisms, which could explain the results obtained 
in this study, justifying the reduction in lipid peroxidation, 
without altering plasma cholesterol levels. 
Thus, endothelial dysfunction reversal may depend on 
other factors in addition to oxidative ones, requiring larger 
doses of pitavastatin for it to occur.
One of the remarkable features of pitavastatin, observed 
from the clinical point of view, is its action in increasing 
HDL, especially in individuals in which it is reduced33,34. 
The main mechanism by which this statin is better than 
others in increasing HDL levels is the capacity to increase 
the expression of ApoA-1 gene, through the activation of 
PPARs35, the largest intra- and extracellular regulator of fatty 
acid metabolism, increasing its secretion.
In the present study, there was a reduction of HDL, 
accompanying a decrease in total cholesterol and LDL levels. 
Pitavastatin did not determine the increase or prevented the 
decrease in HDL, as observed in clinical studies. In another 
experimental study in ovariectomized hypercholesterolemic 
rabbits19, the authors found no significant changes in HDL 
and triglycerides. These findings regarding HDL have been 
observed with other statins in the literature30,32, and they 
were not aimed at specifying the mechanisms by which these 
animals exhibit such behavior. Differences in lipid metabolism 
between species that justify such results should exist and 
should be the objectives of future researches in order to better 
understand this phenomenon. 
The results observed in relation to triglycerides (Table 1 
and Figure 4), showing significant decrease in the treated 
groups, demonstrate the efficacy of pitavastatin in this 
sense, as observed in other experimental studies19,27, which 
would make this statin the choice to treat individuals 
with hypercholesterolemia, as well  as those with 
hypertriglyceridemia, especially diabetic ones. 
The actions of statins, in addition to those dependent 
on the reduction in LDL and cholesterol, are known in 
the literature12,14. Such effects, known as pleiotropic ones, 
have been generally beneficial by reducing lipid oxidation 
and reversing endothelial dysfunction, as demonstrated 
in the present study, in addition to blocking inflammatory 
processes, among others, resulting in the interruption of 
atherosclerosis progression and, consequently, of clinical 
events. However, lately it has been observed that these 
pleiotropic effects may also be deleterious to the body, 
especially in relation to glucose metabolism35.
Although clinical studies have shown controversial results 
regarding the adverse events of statins in inducing diabetes 
as, in the WOSCOPS3 study, pravastatin prevented diabetes 
onset, and in the JUPITER study36, rosuvastatin induced it, 
experimental evidence consistently demonstrate that statins 
may impair glucose homeostasis37. In the present study, there 
was no change in blood glucose levels of treated groups when 
compared to controls. 
Although experimental studies involving pitavastatin and 
adverse events related to glucose metabolism have not been 
performed, clinical studies comparing it to other statins have 
shown that the onset of diabetes in users has been significantly 
lower, especially regarding atorvastatin and rosuvastatin, and 
comparable to pravastatin38. Furthermore, this event has occurred 
when higher doses of statins were used, perhaps justifying the 
results of this study, in which lower doses were used. The same 
result occurred in relation to liver and creatine kinase enzymes, 
which showed no change in the groups treated with pitavastatin 
when compared to controls, demonstrating that the doses used 
were safe (Table 1). This fact has been reported in the literature39.
Conclusion
Pitavastatin was effective in reducing plasma lipids, lipid 
peroxidation and tissue cholesterol, reversing endothelial 
dysfunction in hypercholesterolemic rabbits, starting with 
a 0.5 mg dose.
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